Predictive Oncology (POAI) Short Interest Ratio & Short Volume → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free POAI Stock Alerts $1.17 +0.02 (+1.73%) (As of 10:06 AM ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Predictive Oncology Short Interest DataCurrent Short Volume25,500 sharesPrevious Short Volume11,100 sharesChange Vs. Previous Month+129.73%Dollar Volume Sold Short$65,025.00Short Interest Ratio / Days to Cover1.1Last Record DateMarch 31, 2024Outstanding Shares4,060,000 sharesFloat Size3,940,000 sharesShort Percent of Float0.65%Today's Trading Volume29,127 sharesAverage Trading Volume24,069 sharesToday's Volume Vs. Average121% Short Selling Predictive Oncology ? Sign up to receive the latest short interest report for Predictive Oncology and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPOAI Short Interest Over TimePOAI Days to Cover Over TimePOAI Percentage of Float Shorted Over Time Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story Predictive Oncology Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202425,500 shares $65,025.00 +129.7%0.7%1.1 $2.55 3/15/202411,100 shares $29,304.00 -37.6%0.3%0.5 $2.64 2/29/202417,800 shares $54,824.00 -31.5%0.5%0.9 $3.08 2/15/202426,000 shares $84,500.00 -19.3%0.7%1.3 $3.25 1/31/202432,200 shares $98,854.00 -8.3%0.8%1.9 $3.07 1/15/202435,100 shares $101,088.00 -33.7%0.9%1.9 $2.88 Get the Latest News and Ratings for POAI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. 12/31/202352,900 shares $174,041.00 -15.5%1.4%2.9 $3.29 12/15/202362,600 shares $197,816.00 -26.4%1.6%3.6 $3.16 11/30/202385,000 shares $277,950.00 -13.6%2.2%4.5 $3.27 11/15/202398,400 shares $306,024.00 -4.7%2.5%4.9 $3.11 10/31/2023103,200 shares $309,600.00 -13.5%2.7%4.3 $3.00 10/15/2023119,300 shares $472,428.00 -5.5%3.1%3.9 $3.96 9/30/2023126,300 shares $404,160.00 -32.1%3.2%2.7 $3.20 9/15/2023186,000 shares $597,060.00 -29.7%4.8%2.4 $3.21 8/31/2023264,400 shares $1.14 million -7.8%6.8%2.7 $4.32 8/15/2023286,900 shares $1.37 million -4.9%7.4%2.4 $4.76 7/31/2023301,700 shares $1.75 million -0.5%7.8%2.1 $5.80 7/15/2023303,200 shares $1.77 million +16.3%7.8%1.5 $5.84 6/30/2023260,800 shares $1.27 million +123.7%6.7%1.1 $4.86 6/15/2023116,600 shares $402,270.00 -11.1%3.0%0.5 $3.45 5/31/2023131,100 shares $423,453.00 +40.7%3.4%0.7 $3.23 5/15/202393,200 shares $318,744.00 -49.1%2.5%0.6 $3.42 4/30/2023183,100 shares $520,004.00 +421.7%4.9%1.3 $2.84 4/15/202335,100 shares $266,760.00 -84.3%N/A0.3 $7.60 3/31/2023223,500 shares $73,039.80 +6.9%N/A0.5 $0.33 3/15/2023209,000 shares $68,970.00 -25.3%N/A0.5 $0.33 2/28/2023279,600 shares $119,109.60 +17.1%N/A0.7 $0.43 2/15/2023238,800 shares $103,639.20 -42.8%N/A0.6 $0.43 1/31/2023417,100 shares $221,063.00 +64.0%N/A1 $0.53 1/15/2023254,300 shares $122,699.75 +14.2%N/A0.7 $0.48 12/30/2022222,700 shares $68,279.82 -4.6%N/A0.7 $0.31 12/15/2022233,500 shares $94,007.10 +89.7%N/A0.7 $0.40 11/30/2022123,100 shares $47,405.81 +68.9%N/A0.4 $0.39 11/15/202272,900 shares $19,865.25 -63.7%N/A0.3 $0.27 10/31/2022201,000 shares $54,772.50 +50.9%N/A0.8 $0.27 10/15/2022133,200 shares $40,639.32 -32.4%N/A0.6 $0.31 9/30/2022196,900 shares $70,884.00 +6.4%N/A0.7 $0.36 9/15/2022185,100 shares $71,300.52 +10.4%N/A0.6 $0.39 8/31/2022167,600 shares $67,576.32 -5.6%N/A0.5 $0.40 8/15/2022177,600 shares $77,273.76 -10.6%N/A0.2 $0.44Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story POAI Short Interest - Frequently Asked Questions What is Predictive Oncology's current short interest? Short interest is the volume of Predictive Oncology shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 25,500 shares of POAI short. 0.65% of Predictive Oncology's shares are currently sold short. Learn More on Predictive Oncology's current short interest. What is a good short interest ratio for Predictive Oncology? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. POAI shares currently have a short interest ratio of 1.0. Learn More on Predictive Oncology's short interest ratio. What is a good short interest percentage for Predictive Oncology? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.65% of Predictive Oncology's floating shares are currently sold short. Is Predictive Oncology's short interest increasing or decreasing? Predictive Oncology saw a increase in short interest in March. As of March 31st, there was short interest totaling 25,500 shares, an increase of 129.7% from the previous total of 11,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Predictive Oncology's float size? Predictive Oncology currently has issued a total of 4,060,000 shares. Some of Predictive Oncology's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Predictive Oncology currently has a public float of 3,940,000 shares. How does Predictive Oncology's short interest compare to its competitors? 0.65% of Predictive Oncology's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Predictive Oncology: Heart Test Laboratories, Inc. (0.31%), NanoVibronix, Inc. (0.13%), XWELL, Inc. (1.68%), Avinger, Inc. (3.64%), Silo Pharma, Inc. (2.43%), Oragenics, Inc. (2.07%), Avenue Therapeutics, Inc. (0.64%), Vaccinex, Inc. (1.17%), Exicure, Inc. (2.40%), Fresh Tracks Therapeutics, Inc. (0.17%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Predictive Oncology stock? Short selling POAI is an investing strategy that aims to generate trading profit from Predictive Oncology as its price is falling. POAI shares are trading down $0.15 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Predictive Oncology? A short squeeze for Predictive Oncology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of POAI, which in turn drives the price of the stock up even further. How often is Predictive Oncology's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including POAI, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Heart Test Laboratories Short Squeeze NanoVibronix Short Squeeze XWELL Short Squeeze Avinger Short Squeeze Silo Pharma Short Squeeze Oragenics Short Squeeze Avenue Therapeutics Short Squeeze Vaccinex Short Squeeze Exicure Short Squeeze Fresh Tracks Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:POAI) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden’s $374B Giveaway Into This SectorDTIThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesHow Biden has already won 2024Porter & Company